Shots:

• Lupin will receive multiple milestones fees payments & I’rom will be responsible to conduct clinical trials, registering, distributing, and marketing biosimilar Denosumab in Japan under collaboration with Lupin
• I’rom will exclusively commercialize the product in Japan, upon the successful completion of the clinical trial and receipt of marketing authorization from PMDA
• Denosumab is currently available under two brands i.e., Pralia and Ranmark & is indicated for the treatment of postmenopausal women with osteoporosis who are at a high risk of fracture and the prevention of skeletal-related events in patients with solid tumor bone metastases

Ref: Lupin | Image: Lupin